Hollander, Priscilla
Liu, Jie
Hill, Julie
Johnson, Jeremy
Jiang, Zhi Wei
Golm, Gregory
Huyck, Susan
Terra, Steven G.
Mancuso, James P.
Engel, Samuel S.
Lauring, Brett http://orcid.org/0000-0002-9680-7452
Clinical trials referenced in this document:
Documents that mention this clinical trial
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
https://doi.org/10.1007/s13300-017-0354-4
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin
https://doi.org/10.1080/03007995.2019.1583450
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
https://doi.org/10.1007/s13300-020-00867-1
Funding for this research was provided by:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, in collaboration with Pfizer Inc.,
Article History
Received: 16 November 2017
First Online: 27 December 2017